Patents Assigned to Creagene, Inc.
-
Patent number: 10478479Abstract: The present invention relates to a method for preparing a dendritic cell, a dendritic cell prepared thereby and a use thereof, and more specifically, to a method for preparing a dendritic cell, including: treating a dendritic cell at a maturation stage rather than at an immature stage with an antigen bound to a peptide having a cell membrane permeability to prepare a dendritic cell with improved antigen-presenting ability, a dendritic cell prepared by the method, and an immunotherapeutic agent thereof, a use for anti-tumor vaccines, or a pharmaceutical composition for treating tumors, containing the same.Type: GrantFiled: July 28, 2015Date of Patent: November 19, 2019Assignee: JW CREAGENE INC.Inventors: Yoon Lee, Young-Mok Kim, So-Yeon Kim, Seung-Soo Han, Yong-Soo Bae
-
Patent number: 10350279Abstract: The present invention relates to a method for generating semi-mature dendritic cells by treating immature dendritic cells with the auto-antigen, cytokine, and PGE2 as a target for the treatment of autoimmune diseases, particularly rheumatoid arthritis, in which the levels of NR4A2 and/or UBASH3B at gene or protein are increased more than 2-fold compared to the immature dendritic cells In addition, the present invention relates to a cell therapeutic agent for treating or preventing autoimmune diseases, containing the semi-mature dendritic cells as an active ingredient. The present invention increases the therapeutic efficacy on rheumatoid arthritis retaining responsiveness to the same auto-antigen that being used for preparing semi-mature dendritic cells, thereby enabling cell therapy.Type: GrantFiled: June 23, 2015Date of Patent: July 16, 2019Assignee: JW CREAGENE INC.Inventors: Yong-Soo Bae, Jun-Eui Park, Yun-Ju Woo, Jin-Ah Jang
-
Patent number: 9701942Abstract: The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1? (IL-1?), Interleukin-6 (IL-6), Tumor necrosis factor-? (TNF-?), Interferon-? (IFN-?), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.Type: GrantFiled: May 30, 2013Date of Patent: July 11, 2017Assignee: JW CREAGENE INC.Inventors: Yoon Lee, Hye-Won Kang, Seung-Soo Han, Young-Mok Kim, Yong-Soo Bae, Seo-Hee Ahn
-
Patent number: 9682152Abstract: The present invention relates to IFN-? fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-? protein. The IFN-? fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-? fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-? fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like.Type: GrantFiled: August 7, 2013Date of Patent: June 20, 2017Assignee: JW CREAGENE INC.Inventors: Yong Soo Bae, Seung Ho Hong, Young Hoon Kim, Seung Soo Han, Jin Kim
-
Publication number: 20150202312Abstract: The present invention relates to IFN-? fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN-? protein. The IFN-? fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the INF-? fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved. The IFN-? fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases, including various types of viral infections or the like.Type: ApplicationFiled: August 7, 2013Publication date: July 23, 2015Applicant: JW CREAGENE INC.Inventors: Yong Soo Bae, Seung Ho Hong, Young Hoon Kim, Seung Soo Han, Jin Kim
-
Publication number: 20150125956Abstract: The present invention relates to a composition for maturing dendritic cells, comprising, as a maturation-promoting factor, Interleukin-1? (IL-1?), Interleukin-6 (IL-6), Tumor necrosis factor-? (TNF-?), Interferon-? (IFN-?), Prostaglandin E2 (PGE2), Picibanil (OK432) and/or Poly IC. The composition for maturing dendritic cells of the present invention may have the effects of not only improving the ability of dendritic cells to induce an immune response, but also of decreasing the antigen non-specific immune response of dendritic cells and increasing antigen-specific immune response of dendritic cells, thus maximizing the effects of immunotherapy.Type: ApplicationFiled: May 30, 2013Publication date: May 7, 2015Applicant: JW CREAGENE INC.Inventors: Yoon Lee, Hye-Won Kang, Seung-Soo Han, Young-Mok Kim, Yong-Soo Bae, Seo-Hee Ahn
-
Patent number: 8513028Abstract: The present invention relates to novel uses of the MLN 51 gene or protein. The MLN 51 gene and protein is closely related to the development of rheumatoid arthritis and serve as biomarker and therapeutic target for rheumatoid arthritis, particularly chronic synovitis.Type: GrantFiled: May 8, 2007Date of Patent: August 20, 2013Assignee: Creagene Inc.Inventors: Jin Ah Jang, Dae Seog Lim, Hyun Soo Lee, Yong Soo Bae
-
Publication number: 20100235932Abstract: The present invention relates to a method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for liver cancer using an animal model carrying tumors expressing a human liver cancer-specific antigen, which comprises the steps of: (a) (a1) administering to a normal animal other than human dendritic cells to be analyzed, or (a1) administering to a normal animal other than human a cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the normal animal; (b) (b1) administering to the animal the cancer cell line expressing the human liver cancer-specific antigen to induce cancer in the animal when the step (a1) is performed in the step (a), or (b1) administering to the animal with cancer dendritic cells to be analyzed when the step (a1) is performed in the step (a); and (c) determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for liver cancer by measuring the formation or growth of cancer cells oType: ApplicationFiled: March 13, 2008Publication date: September 16, 2010Applicant: CREAGENE INC.Inventors: Yong-Soo Bae, Hyun-Soo Lee, Mi-Kyung Min, Cheol-Woong Jeong, Kyu-Ho Kang
-
Publication number: 20100215624Abstract: The present invention relates to a pharmaceutical composition for treating rheumatoid arthritis, which comprises (a) a pharmaceutically effective amount of a semi-mature dendritic cell; and (b) a pharmaceutically acceptable carrier. The semi-mature dendritic cell of this invention has a safe and remarkably improved potential to treat or prevent rheumatoid arthritis through the activity of the suppression of auto-immune responses.Type: ApplicationFiled: March 12, 2008Publication date: August 26, 2010Applicant: CREAGENE INC.Inventors: Mi-Sun Kang, Dae-Seog Lim, Ju-Ah Jeong, Hyun-Soo Lee, Yong-Soo Bae
-
Publication number: 20100055076Abstract: A method for preparing dendritic cells which have an enhanced potential to suppress immune responses, method for suppressing immune response by comprising administering them, dendritic cells carrying a potential to suppress immune responses, and a pharmaceutical composition comprising the dendritic cells capable of inducing immunosuppressive responses. The present dendritic cells having an enhanced potential to suppress immune responses can be utilized for treating or preventing various diseases or disorders through the suppression of immune responses. In addition, the enhanced immunotolerance potential of the dendritic cells ensures the cells to be effectively used as an immunosuppressive agent.Type: ApplicationFiled: August 20, 2009Publication date: March 4, 2010Applicant: CREAGENE INC.Inventors: Dae Seog Lim, Ju Ah Jeong, Mi-Sun Kang, Hyun Soo Lee, Yong Soo Bae
-
Publication number: 20090293138Abstract: A method for analyzing the prevention and treatment efficacy of a dendritic cell-derived immunotherapeutic for prostate cancer using an animal model carrying tumors expressing a human prostate cancer-specific antigen includes either administering to a normal non-human animal dendritic cells to be analyzed, or administering to a normal non-human animal a cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the normal non-human animal; administering to the animal the cancer cell line expressing the human prostate cancer-specific antigen to induce cancer in the animal when the dendritic cell administering step was performed, or administering to the animal with cancer dendritic cells to be analyzed when the human prostate cancer-specific antigen expressing cell line administering step was performed; and determining the prevention and treatment efficacy of the dendritic cells as immunotherapeutics for prostate cancer by measuring the formation or growth of cancer cells originaType: ApplicationFiled: May 27, 2006Publication date: November 26, 2009Applicant: CREAGENE, INC.Inventors: Dong Sung Lee, Woo Bok Lee, Choon Ju Jeon, Yong Soo Bae
-
Publication number: 20090029387Abstract: A method for measuring the activity of cytotoxic T lymphocytes (CTLs) includes preparing peripheral blood mononuclear cells (PBMCs) from blood of an animal; preparing mature dendritic cells by isolating monocytes from the PBMCs, differentiating the monocytes into dendritic cells for presenting an antigen molecule and pulsing dendritic cells with the antigen molecule to obtain the mature dendritic cells; preparing the CTLs as an effector cell by stimulating the PBMCs with the mature dendritic cells to activate and amplify the CTLs; preparing target cells by pulsing the PBMCs, monocytes or B cells with a cytoplasmic transduction peptide (CTP)-antigen complex generated by linking the antigen molecule of step (b) to the CTP; treating the target cells with the effector cells; and analyzing the lysis of the target cells. In addition, a kit for measuring the activity of cytotoxic T lymphocytes is provided.Type: ApplicationFiled: May 25, 2006Publication date: January 29, 2009Applicant: CREAGENE, INC.Inventors: Sang Won Jung, Yong Soo Bae, Choon Ju Jeon
-
Patent number: 7138274Abstract: The present invention relates to a novel recombinant Sabin type 1 poliovirus vector for the immunogenicity of neutralizing antibody against polioviral infection, which comprises: (a) a genomic nucleotide sequence of a parent Sabin type 1 poliovirus; (b) a nucleotide sequence encoding an additional polioviral cleavage site; and (c) a nucleotide sequence of a conformational epitope encoding a VP1 neutralizing epitope of poliovirus type 2 or 3 and linked to the nucleotide sequence of (b).Type: GrantFiled: August 26, 2004Date of Patent: November 21, 2006Assignee: Creagene, Inc.Inventors: Yong-Soo Bae, Sang-Gu Lee, Hye-Rhan Jeong, Dong-Sung Lee, Ki-Tae Kim, Dae-You Kim
-
Patent number: 7101844Abstract: The present invention relates to a cytoplasmic transduction peptide (CTP) showing transduction potential, as well as cytoplasmic remaining potential and various uses thereof. The CTP of this invention exhibits a transduction potential identical or higher than the conventional protein transduction, PTD, and a strong tendency to remain in the cytoplasm, so that it is very useful in inducing cytotoxic T lymphocytes (CTL) and a drug delivery system (DDS) targeting cytoplasm.Type: GrantFiled: March 28, 2003Date of Patent: September 5, 2006Assignee: Creagene, Inc.Inventors: Dae-You Kim, Hae-Keun Oh, Chang-Hyun Kim, Jung-Hwan Kim, Choon-Ju Jeon, Ki-Tae Kim, Yong-Soo Bae, In-Soo Choi
-
Patent number: 6780618Abstract: The present invention relates to (a) methods for improving a genetic stability of an insert nucleotide sequence in a recombinant single-stranded RNA virus vector, which comprises performing a mutagenesis of the foreign insert nucleotide sequence to provide even distribution of G/C content throughout the overall foreign insert nucleotide sequence and/or to increase G/C content of the foreign insert without substantially causing amino acids substitutions (b) a recombinant single-stranded RNA virus comprising an insert nucleotide sequence with improved genetic stability and (c) a recombinant poliovirus comprising an insert nucleotide sequence with improved genetic stability.Type: GrantFiled: February 8, 2002Date of Patent: August 24, 2004Assignee: CreaGene Inc.Inventors: Sang-Gu Lee, Dae-You Kim, Ki-Tae Kim, Yong-Soo Bae
-
Patent number: 6696289Abstract: A replication-competent recombinant Sabin type 1 poliovirus vector containing a sequence coding for multiple cloning site and 3C-protease cleavage site is provided. This vector makes it easy to introduce various vaccine genes from infectious viruses to the Sabin 1 poliovirus, and facilitates to produce chimeric Sabin 1 polioviruses that are expected to be powerful oral mucosal vaccines against several infectious viral diseases.Type: GrantFiled: June 4, 1999Date of Patent: February 24, 2004Assignee: Creagene Inc.Inventors: Yong Soo Bae, Hye Rhan Jung